a r t I C l e S The identification of genetic abnormalities that are specific to cancer cells has made it possible to develop targeted treatments. The EGFR is a prime target in this therapeutic approach, since it is overexpressed in many types of cancers and may be a key driver of the malignant phenotype. An exciting development in recent years was the identification of EGFR activating mutations in a subset of lung cancers, which render cells harboring such mutations oncogene addicted and very sensitive to the effects of EGFR tyrosine kinase inhibitors (TKIs) 1, 2 . However, the inevitable development of secondary resistance has limited the effectiveness of EGFR inhibition in lung cancer. The development of secondary resistance in lung cancer has spurred intensive investigation into mechanisms of EGFR TKI resistance and resulted in important insights into secondary resistance to EGFR TKIs in lung cancer. The main mechanisms identified in lung cancer include the emergence of EGFR mutations such as the T790M mutation and activation of other receptor tyrosine kinases, such as Met or Axl, that confer resistance to EGFR TKIs 3 . In addition to genetic and delayed mechanisms, rapid feedback loops with activation of STAT3 (signal transducer and activator of transcription 3) have also been invoked to mediated EGFR TKI resistance in lung cancer cells with EGFR activating mutations 4, 5 . However, most EGFR-expressing tumors in both the lung and the brain do not appear to be oncogene addicted, and EGFR TKIs, so far, have not been effective in such cancers.
EGFR gene amplification and increased EGFR expression are detected in 40-50% of GBMs, the most common primary malignant adult brain tumor 6, 7 . EGFRvIII is the most common oncogenic EGFR mutant in GBM and may be more sensitive to EGFR inhibition 8 . There has been a substantial, and thus far unsuccessful, effort to inhibit the EGFR as a therapeutic strategy in GBM 9 . While not much is known about what mediates primary resistance to EGFR inhibition in GBMs expressing EGFR wild type (EGFRwt), a number of studies have provided key insights into mechanisms that mediate secondary resistance to EGFR inhibitors such as erlotinib in EGFRvIII-expressing glioma cells after an initial period of responsiveness. For example, prolonged EGFR inhibition leads to an increased expression of plateletderived growth factor receptor-β (PDGFRβ) that mediates a secondary resistance to erlotinib 10 . Another study demonstrated that secondary resistance to erlotinib in GBM is mediated via a dynamic downregulation of EGFRvIII 11 . A comparison of erlotinib sensitivity in EGFR lung cancer mutations versus the EGFRvIII mutation suggested that EGFRvIII-containing cancers are resistant to erlotinib because of lower kinase-site occupancy and more rapid cycling of erlotinib 12 . Another study identified a urokinase receptor-Bim signaling axis as mediating EGFR inhibitor resistance 13 .
Primary resistance to EGFR inhibition in cancer cells expressing EGFRwt or resistant EGFR mutants may occur because the EGFR does not drive survival or proliferation of these cells or because adaptive signals prevent cell death. If primary resistance is mediated via an early adaptive response, there is the possibility of inhibiting this adaptive response and overcoming primary resistance to EGFR a r t I C l e S inhibition. Here we show that primary resistance in EGFR-expressing glioma cells is mediated by a rapid adaptive signaling pathway that is triggered by inhibition of EGFRwt or mutant EGFR. We propose that a TNF-JNK-Axl-ERK signaling pathway mediates this adaptive response. Inhibition of this pathway in EGFR-expressing glioma cells confers sensitivity to EGFR inhibition in cell culture, as well as in a mouse model.
RESULTS

Erlotinib induces a feedback activation of ERK in glioma cells
To elucidate mechanisms of EGFR inhibition resistance in glioma cells, we examined signal transduction events following erlotinib exposure in glioma cells. We used EGFR-expressing patient-derived primary GBM neurospheres, as well as established glioblastoma cell lines expressing EGFRwt or EGFRvIII (Fig. 1a) . Signaling from EGFRvIII is constitutive, while signaling from overexpressed EGFRwt may be constitutive or ligand induced 7, [14] [15] [16] [17] [18] [19] . Primary GBM neurospheres GBM9, GBM39 and SK987 express EGFRvIII and also EGFRwt and have been described previously [20] [21] [22] [23] . We started our investigation by examining activation of the serine/threonine kinase Akt, STAT3 and ERK, since these pathways are important in cancer cell survival. Upon exposure of GBM9 neurospheres to erlotinib, the ERK activation present in untreated cells decreased after addition of erlotinib, suggesting that EGFR was driving the activation of ERK. A reactivation of ERK was seen at 24-48 h in erlotinib-treated cells, likely triggered by a feedback mechanism, since the EGFR remained inactivated ( Fig. 1b) . However, we did not detect an increase in Akt or STAT3 activation ( Fig. 1b) . Similar results were obtained in patientderived primary GBM39 and SK987 neurospheres ( Fig. 1c,d) . We also examined signal transduction in established glioblastoma cell lines U87EGFRwt, U87EGFRvIII and U251EGFRwt and found a similar feedback activation of ERK in response to EGFR inhibition (Fig. 1e,f and Supplementary Fig. 1a) . Similar results were also obtained with afatinib, an irreversible direct inhibitor of EGFR kinase activity ( Supplementary Fig. 1b) . When we used a higher concentration of erlotinib, STAT3 and Akt activation were suppressed. However, we did not detect any reactivation of STAT3 or Akt in the presence of continuing EGFR inhibition ( Supplementary Fig. 1c-g) . Thus, of the three pathways examined, only ERK became activated in response to EGFR inhibition. In U87EGFRwt cells, ERK and EGFR activation were similar in serum or serum-free conditions (Supplementary Fig. 1h Patient-derived primary GBM neurospheres (GBM9) were exposed to erlotinib (1 µM) for the indicated times followed by western blot with the indicated antibodies; pMet, pAxl, pERK, pEGFR, pSTAT3 and pAkt specifically detect phosphorylated isoforms. (c,d) A similar experiment in GBM neurospheres derived from two different patients (GBM39 and SK987). (e) U87EGFR cells were treated with erlotinib (1 µM) for the indicated times followed by western blot with the indicated antibodies. (f) A similar experiment was conducted in U87EGFRvIII cells. (g-j) Axl was inhibited using the specific inhibitor R428 (1 µM). Cells were exposed to erlotinib followed by western blot. Erlotinib-induced ERK activation is inhibited when the Axl inhibitor is used in both established GBM cell lines and patient-derived neurospheres. (k-n) siRNA knockdown of Axl results in an inhibition of erlotinib-induced ERK activation in both established cell lines and patient-derived neurospheres. Control siRNA or Axl siRNA was transfected into cells (for 48 h), followed by addition of erlotinib for 48 h and western blot with indicated antibodies. Western blots shown in a-n are representative of at least three independent replicates. Full-length blots are presented in Supplementary Figure 11 .
1 0 7 6 VOLUME 20 | NUMBER 8 | AUGUST 2017 nature neurOSCIenCe a r t I C l e S which blocks binding of ligand to the EGFR, suggesting autocrine activation of EGFR under serum-starved conditions ( Supplementary  Fig. 1i ). As expected, further increases in EGFR and ERK activation were detected when exogenous epidermal growth factor (EGF) was added ( Supplementary Fig. 1j ).
Inhibition of Axl blocks EGFR inhibition mediated ERK activation
Activation of other receptor tyrosine kinases such as Met or Axl has been identified as a major mechanism of secondary resistance to EGFR inhibition in lung cancer cells. In glioma, EGFRvIII expression leads to coactivation of multiple receptor tyrosine kinases, such as Met, and a combined inhibition of EGFR and Met or of Akt and the mechanistic target of rapamycin (mTOR) is more effective than inhibition of the EGFR alone [24] [25] [26] [27] [28] [29] . Increased expression of PDGFRβ has been described in response to prolonged EGFR inhibition in glioma cells 10 . We detected phosphorylation of the receptor tyrosine kinase Axl following exposure of cells to erlotinib for 48 h in patientderived GBM neurospheres and in all cell lines examined ( Fig. 1b-f and Supplementary Fig. 1a ). Erlotinib also induced activation of Met in established cell lines, but in only one patient-derived neurosphere, SK987 ( Fig. 1b-f and Supplementary Fig. 1a ). Since Axl activation was seen in all patient-derived neurospheres and established cell lines tested, we focused on Axl in this study. We next examined whether Axl was responsible for activation of ERK in response to EGFR inhibition. We used the Axl inhibitor R428 and found that inhibition of Axl resulted in a block of erlotinibinduced ERK activation in patient-derived GBM neurospheres, as well as in multiple cell lines ( Fig. 1g-j) . Similarly, short interfering RNA (siRNA) knockdown of Axl also resulted in a block of erlotinibinduced ERK activation ( Fig. 1k-n) . Thus, Axl is essential to EGFRinduced inhibition of ERK activation.
Activation of JNK by EGFR inhibition triggers a survival feedback loop
We next examined whether inhibition of key signaling pathways known to be active in EGFR signaling could block erlotinib-induced Axl and ERK activation. We found that the JNK inhibitor SP600125 inhibited erlotinib-induced activation of Axl and ERK in patientderived neurospheres and in established GBM cell lines, but the p38 mitogen-associated protein kinase (MAPK) inhibitor SB203580 failed to do so ( Fig. 2a-d) . We also found that siRNA knockdown of JNK1 and JNK2 resulted in a block of erlotinib-induced EGFR Axl and ERK activation ( Fig. 2e-g) . Furthermore, erlotinib exposure of cells resulted in activation of JNK as detected by phosphorylation of JNK in western blots ( Fig. 2 h-k) . These findings suggest that JNK activation is essential to erlotinib-induced ERK activation. JNK proteins are MAPKs that phosphorylate c-Jun. This results in activation of the transcription factor AP-1. Consistent with data demonstrating JNK activation in response to EGFR inhibition, erlotinib also induced increased activity of the AP-1 reporter (Fig. 2l) . These experiments a r t I C l e S support a model in which EGFR inhibition leads to the activation of JNK signaling and, in turn, JNK signaling mediates an activation of Axl. Axl activation then leads to ERK activation. EGFR inhibition has also been reported to result in a rapid activation of NF-κB in lung cancer cells expressing activating EGFR mutations 30 . However, we did not detect an increase in NF-κB transcriptional activity in response to EGFR inhibition in glioma cells, whereas lipopolysaccharide efficiently activated NF-κB transcriptional activity ( Supplementary Fig. 2a,b ).
Activation of Axl results from increased expression of GAS6
Next we examined the mechanism of Axl activation following exposure to erlotinib. Axl was activated about 24-48 h after the EGFR was inhibited. We investigated the possibility that erlotinib may lead to increased expression of GAS6, the ligand for Axl. We examined the erlotinib-induced expression of GAS6 at various time points by realtime quantitative PCR. EGFR inhibition led to an increase in GAS6 in patient-derived neurospheres and in established GBM cell lines ( Fig. 3a-d) . Notably, inhibition of JNK blocked erlotinib-induced expression of GAS6 ( Fig. 3a-d) , consistent with the previously noted inhibition of erlotinib-induced Axl activation by chemical inhibition or silencing of JNK. An increase in GAS6 was confirmed by ELISA and western blot ( Fig. 3e,f) . These findings suggest that erlotinib-induced activation of Axl likely results from an increase in GAS6. Next, we examined whether activation of JNK leads to increased transcription of GAS6. The TFBIND program identified multiple predicted c-Jun (AP-1) binding sites 500 bp upstream of the putative transcription start site of GAS6 (Fig. 3g) . We then undertook a chromatin immunoprecipitation (ChIP) assay to investigate the presence of AP-1 at the GAS6 promoter. Erlotinib exposure led to the binding of c-Jun to the GAS6 promoter in GBM9 and U87EGFRwt cells ( Fig. 3h,i) .
JNK is activated by an erlotinib-induced increase in TNF Next we examined the mechanism of erlotinib-induced JNK activation. Previous studies have found that EGFR inhibition in lung cancer cells results in increased secretion of inflammatory cytokines 5 . We hypothesized that EGFR inhibition in glioma cells may lead to a similar release of cytokines. Since TNF is a known and potent activator of JNK 31 , we quantified TNF in patient-derived GBM neurospheres, as well as EGFRexpressing cell lines. Erlotinib led to a significant and rapid increase in TNF mRNA, as determined by real-time quantitative PCR ( Fig. 4a-d) . The increase in TNF was confirmed at a protein level by ELISA (Fig. 4e) . The increase in TNF was noted in additional lines and patient-derived neurospheres ( Supplementary Fig. 2c,d) . Notably, an increase in TNF was also induced by EGFR inhibition in tumors growing in mice ( Fig. 4f) . In this experiment, patient-derived primary GBM9 cells were injected into the flanks of athymic mice. After formation of a palpable tumor, erlotinib was administered as indicated, followed by collection of tumors and ELISA for TNF. An erlotinib-induced increase in TNF was detected 1 d after administration of erlotinib ( Fig. 4f) . In addition, we also detect erlotinib-induced activation of JNK, Axl and ERK in mouse tumors ( Fig. 4g) , peaking around 2-7 d and subsiding by 14 d.
Next we examined whether TNF is essential role in erlotinibinduced JNK activation. We indeed found that a neutralizing antibody to TNF led to inhibition of erlotinib-induced JNK activation ( Fig. 4h) . Furthermore, erlotinib-induced Axl and ERK activation were also blocked by TNF inhibition. Similar results were found with siRNA knockdown of TNF receptor 1 (TNFR1) ( Fig. 4i) . We also examined levels of TNFR1 in glioma cells treated with erlotinib. Erlotinib induced a downregulation of TNFR1 in patient-derived samples and established GBM cell lines (Supplementary Fig. 2e ). As TNF induces downregulation of its receptor 32 , this finding provides evidence that TNF signaling is activated by EGFR inhibition.
Inhibition of the TNF-JNK-Axl-ERK axis confers erlotinib sensitivity on EGFR-expressing glioma cells
To investigate whether this TNF-JNK-Axl-ERK signaling pathway influences the biological response to EGFR inhibition, we examined the effect of inhibiting this pathway on the viability of glioma cells exposed to erlotinib. First we examined the sensitivity of EGFRexpressing GBM cell lines to erlotinib. The established cell lines appeared to be completely resistant to erlotinib regardless of whether EGFRwt or EGFRvIII is expressed ( Fig. 5a) . Patient-derived primary neurosphere GBM9 and GBM39 cells were resistant to EGFR inhibition at a low concentration of erlotinib (100 nM). However, when combined with JNK inhibition using SP600125 or ERK inhibition using U0126, erlotinib led to substantial cell death, although cells were resistant to JNK or ERK inhibition alone (Fig. 5b,c) . Inhibitors of several other signaling pathways failed to sensitize glioma cells to EGFR inhibition (Supplementary Fig. 2f ). Established glioblastoma cell lines were also resistant to EGFR inhibition or JNK inhibition or ERK inhibition alone, but a combined inhibition of EGFR with ERK b a a r t I C l e S or JNK led to substantial cell death ( Fig. 5d,e ). Biological inhibition of JNK using siRNA knockdown also rendered glioma cells sensitive to EGFR inhibition (Fig. 5f-h and Supplementary Fig. 2g ).
Next we examined whether inhibition of Axl would also render resistant glioma cells sensitive to EGFR inhibition, since Axl inhibition blocks the erlotinib-induced ERK activation. A specific chemical inhibitor of Axl, R428, indeed rendered patient-derived GBM neurospheres and U87EGFRwt cells sensitive to erlotinib (Fig. 5i-k) . R428 by itself did not affect the viability of these cells. Axl inhibition also conferred sensitivity to erlotinib in established GBM cell lines (Fig. 5j) . Similarly, siRNA knockdown of Axl also conferred erlotinib sensitivity on GBM9, GBM39 and U87EGFR cells (Fig. 5l-n and Supplementary Fig. 2h) .
Finally, we examined whether inhibition of TNF signaling could render glioma cells sensitive to erlotinib. Inhibition of TNF signaling with the use of etanercept (Enbrel) indeed rendered patient-derived primary GBM neurospheres, as well as established GBM cell lines, sensitive to the effects of EGFR inhibition (Fig. 6a-c) . Similarly, siRNA knockdown of TNFR1 also resulted in increased sensitivity of cells to EGFR inhibition (Fig. 6d-f and Supplementary Fig. 2i ). Furthermore, the use of thalidomide, an inhibitor of TNF 33 , also had the same effect ( Fig. 6g-i) . Thalidomide may inhibit other cytokines, and we confirmed that thalidomide did indeed block the erlotinibinduced increase in TNF secretion in glioma cell lines ( Supplementary  Fig. 3a,b) . We also confirmed that the use of etanercept or thalidomide resulted in an interruption of the erlotinib-induced activation of the JNK-Axl-ERK signaling pathway ( Fig. 6j-l) . In addition, a neutralizing antibody to TNF also enhanced sensitivity of both patient-derived and established GBM lines to EGFR inhibition ( Supplementary  Fig. 3c,d) . Afatinib, an irreversible inhibitor of EGFR kinase, in combination with thalidomide had a similar effect ( Supplementary  Fig. 3e,f) . Thus, interruption of the adaptive TNF-JNK-Axl-ERK signaling axis at any node renders resistant glioma cells sensitive to EGFR inhibition.
Conversely, activation of TNF signaling by addition of exogenous TNF resulted in protection from cell death induced by EGFR inhibition in patient-derived primary GBM neurospheres. In this experiment, we used a erlotinib concentration of 1 µM, which induces substantial cell death in these cells. Addition of exogenous TNF protected patient-derived primary GBM9 and GBM39 from cell death induced by EGFR inhibition (Fig. 6m,n) . We also measured changes in cell viability by flow cytometry for annexin V and caspase 3/7 activation Figs. 4-7) . Glioma cells underwent apoptotic cell death when erlotinib was used in combination with Axl, JNK, ERK or TNF inhibition. Finally, we examined cell proliferation in a cell counting assay. Erlotinib used in combination with Axl, JNK, ERK or TNF inhibition produced significant (P < 0.01) decreases in cell numbers in response to combined inhibition of EGFR and JNK, Axl or ERK (Supplementary Fig. 8 ).
Inhibiting the adaptive response renders primarily resistant glioma cells sensitive in a mouse model Erlotinib-induced JNK activation appears to orchestrate the adaptive response underlying primary resistance of glioma cells to EGFR inhibition. Thus, we examined the effect of inhibiting JNK in a xenograft model in which we injected patient-derived GBM9 neurospheres into the flanks of athymic mice. Once subcutaneous tumors became visible, we divided the mice into control gavage, erlotinib alone, JNK inhibitor (SP600125) alone or erlotinib + SP600125 groups. Erlotinib was administered to animals by oral gavage (50 mg/kg) 23 for 10 d and SP6001125 was administered 34 at a concentration of 40 mg/kg intraperitoneally daily for 10 d. The combined inhibition of JNK and EGFR strongly inhibited the growth of tumors, whereas SP600125 or erlotinib alone had no significant effect on it (Fig. 7a) .
Next we examined the effect of a combined inhibition of TNF and EGFR. We used thalidomide to inhibit TNF because thalidomide is known to penetrate the blood-brain barrier and has been previously used in GBM (although not in combination with EGFR inhibition) 35 . The experiment was conducted by injecting patient-derived GBM9 neurospheres in the flanks of athymic mice. Once subcutaneous tumors became visible, the mice were divided into control gavage, erlotinib alone, thalidomide alone or erlotinib + thalidomide groups. Erlotinib was administered to animals by oral gavage (50 mg/kg) daily for 10 d and thalidomide was administered at a concentration of 150 mg/kg intraperitoneally daily for 10 d 34, 36 . The combined inhibition of TNF and EGFR strongly inhibited the growth of tumors, whereas thalidomide or erlotinib alone had no significant effect on it (Fig. 7b) .
Next we undertook an orthotopic experiment in athymic mice. Patient-derived GBM9 cells were implanted intracranially, followed by bioluminescence imaging. As we have described recently, GBM9 neurospheres rapidly form tumors in an intracranial model 20 . When tumors became visible on bioluminescence imaging, the mice were divided into four groups and treated with control, erlotinib alone, thalidomide alone or a combination of erlotinib and thalidomide. While neither erlotinib nor thalidomide alone had a significant effect, the combined treatment resulted in a highly significant improved survival of mice treated with a combination of EGFR and TNF inhibition (Fig. 7c,d) . We repeated the orthotopic experiment with afatinib, another EGFR inhibitor, with similar results (Supplementary Fig. 9a,b) . In our animal experiments, erlotinib or afatinib was used in combination with thalidomide or SP600125 for a total of 10 d without appreciable short-term toxicity up to the time the mice were sacrificed. The effects of these interventions on the body weight of mice are shown in Supplementary Figure 9c-f .
Activation of the JNK-Axl-ERK signaling axis was detectable by western blot in intracranial tumors in mice exposed to erlotinib for various time points (Fig. 7e,f) . We also examined the effect of therapeutic intervention and found that use of a TNF inhibitor (thalidomide) blocked the EGFR inhibition-induced upregulation of the TNF-JNK-Axl-ERK signaling axis in intracranial tumors. (Fig. 7g) . The temporal profile of this activation was similar to that noted in the subcutaneous model ( Fig. 4g) and showed an increased activation of this pathway peaking at 2-7 d and subsiding by 14 d. We also examined activation of JNK, Axl and ERK by immunohistochemistry ( Supplementary Fig. 10) . The results are consistent with our western blot results and show that EGFR inhibition led to activation of the JNK-Axl-ERK signaling axis and that administration of a TNF inhibitor (thalidomide) blocked activation of this pathway.
DISCUSSION
The main finding in our study is that EGFR inhibition in glioma cells results in triggering of a rapid adaptive response that mediates resistance to EGFR inhibition. If this adaptive response is blocked, glioma cells with primary or intrinsic resistance become sensitive to EGFR inhibition and undergo cell death following cessation of EGFR signaling. Previous studies have shown that inhibition of specific tyrosine kinases or key downstream signals in cancer cells leads to a feedback-mediated escape from pathway inhibition by reprogramming of signaling pathways that frequently leads to a resumption of previously suppressed signals or activation of alternative signals that are functionally similar 37, 38 . Thus, the cancer cell tends to maintain homeostasis, and it is likely that such mechanisms are an important contributor to drug resistance. Our study demonstrates that a TNF-JNK-Axl-ERK signaling axis mediating an adaptive response to EGFR inhibition in glioma cells is triggered in response to EGFR inhibition. Inhibition of this adaptive response in combination with EGFR inhibition is effective in treatment of glioma tumors in a mouse model.
EGFR gene amplification and overexpression are found in 40-50% of GBMs, and about half of these tumors express the constitutively active oncogenic mutant EGFRvIII 7,39 . EGFRvIII does not bind ligand and is considered constitutively active, although recent studies have revealed a role of coexpressed EGFRwt in the activation of EGFRvIII 40, 41 . Studies have demonstrated that EGFRvIII has a greater oncogenic potential than EGFRwt 39 . Recent studies have provided key insights into EGFRvIII downstream signaling and found STAT3 to be a key downstream signal [41] [42] [43] . However, EGFRwt may also be oncogenic in GBM 16 . Activation of EGFRwt may be mediated by coexpression of EGFR ligands in the tumor, and studies have documented the presence of EGFR ligands in GBM 14, 18 . In addition, overexpression of EGFRwt may also result in a ligand-independent constitutive signaling 14, 15, 17, 18 . Thus, EGFR signaling is likely to be active in GBM cells that express either constitutively active EGFR mutants or EGFRwt. Furthermore, EGFR signaling in patient-derived primary GBM neurospheres, as well as in established GBM cell lines, appears to influence cell survival, since EGFR inhibition in combination with blockade of the TNF-JNK-Axl-ERK adaptive response resulted in cell death both in patient-derived primary GBM cells and in established GBM cell lines. Inhibition of the TNF-JNK-Axl-ERK axis in the absence of EGFR inhibition had no appreciable effect on GBM cell viability.
Many efforts to inhibit the EGFR have failed in GBM 9 , the most recent being the failure of a vaccine against EGFRvIII. The first study of targeted EGFR TKI in GBM involved a single-arm phase II trial of gefitinib at first recurrence. No radiographic responses were noted, and median overall survival was about 39 weeks 44 . Subsequent studies with erlotinib in recurrent GBM were also not effective. Trials of EGFR TKIs in combination with temozolomide and radiation in newly diagnosed GBM have not demonstrated improved outcomes 45, 46 . Another treatment strategy involves targeting the EGFRvIII mutation with a vaccine (rindopepimut) consisting of a peptide conjugated to keyhole limpet hemocyanin designed to generate a specific immune response against tumor cells with EGFRvIII mutations. A phase II multicenter trial of rindopepimut in newly diagnosed GBM demonstrated a median overall survival of 21.8 months and a 3-year survival of 26%, a r t I C l e S suggesting some early promise of efficacy 47 . However, interim analysis of the subsequent phase III study of rindopepimut plus temozolomide in newly diagnosed GBM (ACT IV) demonstrated no difference in median overall survival compared to temozolomide plus control keyhole limpet hemocyanin injections, and thus the trial was discontinued early (https://clinicaltrials.gov identifier NCT01480479).
The dynamic complexity of the glioblastoma genome poses a formidable challenge to effective treatment. Tumor heterogeneity may also limit the effectiveness of EGFR inhibition 48, 49 . We propose that the many failures of anti-EGFR therapy in GBM may have resulted, at least in part, from a rapid adaptive response triggered by an increase in TNF signaling. TNF is a central player in the inflammatory response and also in the pathogenesis of cancer. Depending on the cellular context, TNF signaling may promote cell survival or cell death. Our findings indicate that TNF is the primary mediator of intrinsic resistance to EGFR inhibition and promotes cell survival in response to a loss of EGFR signaling via activation of JNK. JNK, in turn, increases expression of GAS6, a ligand for the Axl receptor. Inhibition of TNF or JNK blocks erlotinib-induced Axl activation. Axl activation, in turn, leads to ERK activation. Interruption of the TNF-JNK-Axl-ERK axis at any node resulted in increased sensitivity to EGFR inhibition. In GBM xenograft tumors, erlotinib induced an upregulation of TNF in about 24 h and TNF levels subsided in about a week, while the JNK-ERK-Axl activation subsided in about 2 weeks. It is thus not feasible to detect EGFR inhibition-induced TNF upregulation or JNK-ERK-Axl activation in archival tissue from patients following erlotinib treatment because tissue is not sampled at early time points after TKI treatment. It is likely that key mechanisms of secondary resistance such as a downregulation of EGFRvIII or upregulation of PDGFRβ also contribute to the failure of anti-EGFR treatment 10, 11 . Similarly, a urokinase receptor-Bim signaling axis may also contribute to EGFR inhibition resistance 13 .
GBM is a devastating and intractable disease. Temozolomide is the first-line chemotherapy drug used in GBM and, in combination with surgery and radiation, results in a modest increase in overall survival of patients 50 . No targeted treatment has proven effective in GBM. Our data indicate that EGFR inhibition may be effective if combined with inhibition of a component of the TNF-JNK-Axl-ERK signaling axis. Remarkably, the combined inhibition of EGFR and the TNF pathway was effective even in established GBM cell lines that are otherwise completely resistant to EGFR inhibition. The identification of this TNF-JNK-Axl-ERK signaling axis suggests that it may be possible to target and inhibit this adaptive response at multiple nodes, alone or in combination. We have found EGFR inhibition in conjunction with JNK inhibition to be effective in an animal model. Additionally, a combination of EGFR inhibition and thalidomide was also very effective in suppressing the growth of GBM tumors in both a subcutaneous and an intracranial animal model. Thalidomide crosses the blood-brain barrier and, indeed, has been previously used clinically in GBM without success 35 . This is consistent with our results that show no effect of thalidomide in the absence of EGFR inhibition. Notably, this approach was effective in both EGFRwt and mutant EGFRvIII-expressing tumors. EGFR expression is detected in most GBMs, and thus this approach could be broadly applicable in this disease. Furthermore, a rapid translation of these findings to the clinic is possible, given the wealth of TNF-inhibiting drugs and biologicals in clinical practice, including drugs such as thalidomide that penetrate the blood-brain barrier.
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